Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo(16.5.2.02,6.07,12.021,25)pentacosa-1(24),7,9,11,18(25),19,22-heptaen-17-one
2. Loxo-195
1. Loxo-195
2. 2097002-61-2
3. Loxo195
4. (6r,15r)-9-fluoro-15-methyl-2,11,16,20,21,24-hexazapentacyclo[16.5.2.02,6.07,12.021,25]pentacosa-1(24),7(12),8,10,18(25),19,22-heptaen-17-one
5. 0j45910s3x
6. Unii-0j45910s3x
7. Selitrectinib [inn]
8. Loxo 195(selitrectinib)
9. Selitrectinib [who-dd]
10. Chembl4297627
11. Schembl18823882
12. Gtpl10314
13. Selitrectinib Pound Loxo-195)
14. Ex-a1873
15. Xid00261
16. Bdbm50507492
17. Nsc809970
18. S8636
19. Akos037648883
20. Db14896
21. Nsc-809970
22. Bay 2731954
23. Bay-2731954
24. (13e,14e,22r,6r)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one
25. Ac-32662
26. Bs-15941
27. Example 28 [wo2017075107a1]
28. Hy-101977
29. Cs-0022378
30. A934608
31. (13e,14e,22r,6r)-35-fluoro-6-methyl-7-aza-1(5,3)pyrazolo[1,5-a]pyrimidina-3(3,2)pyridina-2(1,2)pyrrolidinacyclooctaphan-8-one
32. (22r,6r)-35-fluoro-6-methyl-1(5,3)-pyrazolo(1,5-a)pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one
33. 12h-15,17-ethenopyrazolo[3,4-d]pyrido[2,3-k]pyrrolo[2,1-m][1,3,7]triazacyclotridecin-12-one, 5-fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-, (3ar,10r)-
34. 12h-5,7-ethenopyrazolo(3,4-d)pyrido(2,3-k)pyrrolo(2,1-m)(1,3,7)triazacyclotridecin-12-one, 5-fluoro-1,2,3,3a,8,9,10,11-octahydro-10-methyl-, (3ar,10r)-
35. Cas Registry Number 2097002-61-2 ~1~1 C20 H21 F N6 O 10h-5,7-ethenopyrazolo(3,4-d)pyrido(2,3-k)pyrrolo(2,1-m)(1,3,7)triazacyclotridecin-10-one, 17-fluoro-1,2,3,11,12,13,14,18b-octahydro-12-methyl-, (12r,18br)-
| Molecular Weight | 380.4 g/mol |
|---|---|
| Molecular Formula | C20H21FN6O |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 0 |
| Exact Mass | 380.17608748 g/mol |
| Monoisotopic Mass | 380.17608748 g/mol |
| Topological Polar Surface Area | 75.4 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 593 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
A LOXO 195 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of LOXO 195, including repackagers and relabelers. The FDA regulates LOXO 195 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. LOXO 195 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A LOXO 195 supplier is an individual or a company that provides LOXO 195 active pharmaceutical ingredient (API) or LOXO 195 finished formulations upon request. The LOXO 195 suppliers may include LOXO 195 API manufacturers, exporters, distributors and traders.
LOXO 195 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of LOXO 195 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right LOXO 195 GMP manufacturer or LOXO 195 GMP API supplier for your needs.
A LOXO 195 CoA (Certificate of Analysis) is a formal document that attests to LOXO 195's compliance with LOXO 195 specifications and serves as a tool for batch-level quality control.
LOXO 195 CoA mostly includes findings from lab analyses of a specific batch. For each LOXO 195 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
LOXO 195 may be tested according to a variety of international standards, such as European Pharmacopoeia (LOXO 195 EP), LOXO 195 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (LOXO 195 USP).
LOOKING FOR A SUPPLIER?
